190 related articles for article (PubMed ID: 12192546)
1. Management of thyroid eye disease.
Bartalena L; Marcocci C; Tanda L; Pinchera A
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S458-65. PubMed ID: 12192546
[TBL] [Abstract][Full Text] [Related]
2. Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches.
Krassas GE
Pediatr Endocrinol Rev; 2003 Dec; 1 Suppl 2():223-9; discussion 229. PubMed ID: 16444162
[TBL] [Abstract][Full Text] [Related]
3. Treating severe Graves' ophthalmopathy.
Bartalena L; Marcocci C; Pinchera A
Baillieres Clin Endocrinol Metab; 1997 Oct; 11(3):521-36. PubMed ID: 9532337
[TBL] [Abstract][Full Text] [Related]
4. Thyroid-associated ophthalmopathy in juvenile Graves' disease--clinical, endocrine and therapeutic aspects.
Krassas GE; Gogakos A
J Pediatr Endocrinol Metab; 2006 Oct; 19(10):1193-206. PubMed ID: 17172081
[TBL] [Abstract][Full Text] [Related]
5. Management of Graves' ophthalmopathy: reality and perspectives.
Bartalena L; Pinchera A; Marcocci C
Endocr Rev; 2000 Apr; 21(2):168-99. PubMed ID: 10782363
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
7. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey.
Weetman AP; Wiersinga WM
Clin Endocrinol (Oxf); 1998 Jul; 49(1):21-8. PubMed ID: 9797843
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N
Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076
[TBL] [Abstract][Full Text] [Related]
9. Thyroid eye disease: therapy in the active phase.
Bhatti MT; Dutton JJ
J Neuroophthalmol; 2014 Jun; 34(2):186-97. PubMed ID: 24821102
[TBL] [Abstract][Full Text] [Related]
10. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.
Bartalena L
J Clin Endocrinol Metab; 2011 Mar; 96(3):592-9. PubMed ID: 21190983
[TBL] [Abstract][Full Text] [Related]
11. Combined radiotherapy and medical immunosuppression in the management of thyroid eye disease.
Claridge KG; Ghabrial R; Davis G; Tomlinson M; Goodman S; Harrad RA; Potts MJ
Eye (Lond); 1997; 11 ( Pt 5)():717-22. PubMed ID: 9474324
[TBL] [Abstract][Full Text] [Related]
12. [Graves' ophthalmopathy: diagnosis and highlights on etiopathogenesis and treatment].
Kamoun M; Abid H; Lamine F; Slimane H; Haddad A
Tunis Med; 2003 Mar; 81(3):149-55. PubMed ID: 12793063
[TBL] [Abstract][Full Text] [Related]
13. Optic neuropathy and diplopia from thyroid eye disease: update on pathophysiology and treatment.
Johnson BT; Jameyfield E; Aakalu VK
Curr Opin Neurol; 2021 Feb; 34(1):116-121. PubMed ID: 33278144
[TBL] [Abstract][Full Text] [Related]
14. Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy.
Marcocci C; Marinò M; Rocchi R; Menconi F; Morabito E; Pinchera A
J Endocrinol Invest; 2004 Mar; 27(3):272-80. PubMed ID: 15165004
[TBL] [Abstract][Full Text] [Related]
15. [The treatment of hyperthyroidism caused by Graves' disease; a decisional approach].
Schaper NC; Hunink MG; Casparie AF
Ned Tijdschr Geneeskd; 1986 Aug; 130(32):1443-50. PubMed ID: 2430195
[No Abstract] [Full Text] [Related]
16. Somatostatin analogues in the treatment of thyroid eye disease.
Krassas GE
Thyroid; 1998 May; 8(5):443-5. PubMed ID: 9623741
[TBL] [Abstract][Full Text] [Related]
17. Graves ophthalmopathy. Results of transantral orbital decompression performed primarily for cosmetic indications.
Fatourechi V; Garrity JA; Bartley GB; Bergstralh EJ; DeSanto LW; Gorman CA
Ophthalmology; 1994 May; 101(5):938-42. PubMed ID: 8190484
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroids in the medical treatment of thyroid ophthalmopathy: when and how? Somatostatin analogues: where we stand today.
Krassas GE; Gogakos A; Boboridis K
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():204-9. PubMed ID: 20467364
[TBL] [Abstract][Full Text] [Related]
19. [Effect of radical treatment of Basedow's disease on the ocular symptoms].
Lederer J
Ann Endocrinol (Paris); 1974; 35(1):79-81. PubMed ID: 4138226
[No Abstract] [Full Text] [Related]
20. An update on medical management of Graves' ophthalmopathy.
Bartalena L; Marcocci C; Tanda ML; Piantanida E; Lai A; Marinò M; Pinchera A
J Endocrinol Invest; 2005 May; 28(5):469-78. PubMed ID: 16075933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
